Electrolyte Replacement Preparations (Sodium, Potassium, Magnesium & Osmolarity)
Electrolyte Replacement Preparations (Sodium, Potassium, Magnesium & Osmolarity) is classified under Group A (Evidence-Supported Sports Nutrition & Ergogenic Aids). While specific physiological and performance benefits are supported in peer-reviewed sports nutrition literature, dietary supplements are not universally safe, cannot replace whole-food nutrition, and carry real risks of undeclared prohibited-substance contamination (10–25% of uncertified commercial supplements). Always consult a qualified physician, pharmacist, or accredited sports dietitian.
1. Generic or Accepted Substance Name & Classifications
Accepted Name: Electrolyte Replacement Preparations (Sodium, Potassium, Magnesium & Osmolarity)
Common Names, Synonyms & Classifications: Oral Rehydration Salts (WHO Low-Osmolarity ORS 245 mOsm/L) IP; Sports Electrolyte Drinks; Sodium Chloride & Citrate Solutions
Section Classification: Group A — Evidence-Supported Sports Nutrition & Ergogenic Aids (PERF-A07)
2. Pharmacological Class
Fluid-Electrolyte Homeostasis & SGLT1 Water-Cotransport Restoration Formulations
3. Mechanism of Action
Replaces sweat sodium (typically 20–80 mmol/L = 460–1,840 mg Na⁺/L of sweat), chloride, and potassium losses incurred during prolonged exercise in hot/humid environments (such as Indian summer and monsoon conditions). Sodium maintains extracellular fluid osmolarity, sustains thirst drive, stimulates renal antidiuretic hormone (ADH)/aldosterone retention, and powers jejunal SGLT1 sodium-glucose cotransport to accelerate intestinal water absorption.
4. Proposed Performance or Endurance Effects (Pharmacological Effect vs Proven Athletic Outcome)
Pharmacological/Physiological Effect: Prevents hypovolaemic cardiovascular drift (>2% body-mass dehydration) and exercise-associated hyponatraemia (EAH). Proven Athletic Performance Benefit: Preserves stroke volume, thermoregulatory cutaneous blood flow, and endurance work capacity in prolonged heat exposure (>60–90 minutes). Unsupported Claims: Electrolyte tablets alone do not prevent all exercise-associated muscle cramps (EAMC), which are multifactorial (involving neuromuscular spindle/Golgi tendon organ fatigue as well as heavy 'salty' sweat losses).
5. Quality of Scientific Evidence
Evidence Assessment: High / Level A Consensus (WHO/IP ORS Compendia, IOC & ACSM Fluid Replacement Guidelines)
6. Approved Medical Uses (Where Applicable)
Oral Rehydration Salts (ORS IP — 245 mOsm/L: Na⁺ 75 mmol/L, K⁺ 20 mmol/L, Cl⁻ 65 mmol/L, Citrate 10 mmol/L, Anhydrous Glucose 75 mmol/L) is an NLEM 2022 and IP 2022 life-saving medicine for acute diarrhoeal dehydration and heat exhaustion.
7. Sports-Related Uses, Misuse Patterns & Contamination Risks
Tailored to sweat rate and sweat sodium concentration during prolonged heat training. Misuse includes: (1) overdrinking plain hypotonic water above sweat rate during marathons, causing life-threatening dilutional Exercise-Associated Hyponatraemia (EAH, serum Na⁺ < 130–135 mmol/L) and cerebral oedema; or (2) purchasing high-sugar commercial beverages falsely marketed as 'ORS' (CDSCO/FSSAI strictly prohibit non-WHO formulas from using the 'ORS' medical label).
8. Adverse Effects & Serious Safety Risks
Hypernatraemia, hypertension, and peripheral oedema if concentrated salt tablets are ingested without adequate water; nausea/vomiting if hypertonic salt solutions are consumed rapidly.
9. Contraindications & Precautions
Anuric renal failure, severe decompensated congestive heart failure, uncontrolled hypertension, or intestinal obstruction/paralytic ileus.
10. Drug Interactions
Lithium carbonate (sodium depletion causes lithium toxicity; high sodium loads increase renal lithium excretion); ACE inhibitors, ARBs, and potassium-sparing diuretics (Spironolactone, Eplerenone) increase hyperkalaemia risk with potassium-rich electrolyte salts.
11. Clinical & Laboratory Monitoring Considerations
Pre- and post-exercise nude/dry body weight (1 kg weight loss ≈ 1 L net fluid deficit; avoid gaining weight during endurance events to prevent EAH); inspect urine colour and monitor for neurological signs of hyponatraemia (confusion, headache, vomiting).
12. Dependence, Misuse or Withdrawal Concerns
No dependence.
13. Regulatory & Legal Status in India (CDSCO / Drugs Rules / NDPS / FSSAI)
WHO-formula Oral Rehydration Salts (ORS) IP is a compendial drug in IP 2022 and NLEM 2022 ([5.19]); non-medical sports electrolyte beverages are regulated under FSSAI FSDU regulations (FSSAI directives prohibit misleading use of the medical 'ORS' title on high-sugar fruit beverages).
14. Official WADA Prohibited-List Status
NOT PROHIBITED via oral route. (Note: Intravenous fluid infusions >100 mL per 12 hours outside hospital/emergency medical care are prohibited under WADA M2.2).
15. Authoritative Source References & Date of Last Verification
Date of Last Verification: 11 November 2026